Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor‐related arthralgia: A randomized trial. Issue 23 (30th July 2014)

• Record Type: Journal Article
• Authors: Mao, Jun J.; Farrar, John T.; Bruner, Deborah; Zee, Jarcy; Bowman, Marjorie; Seluzicki, Christina; DeMichele, Angela; Xie, Sharon X.
• Is Part Of: Cancer. Volume 120:Issue 23(2014)
• Page Start: 3744
• Page End: 3751
• Publication Date: 2014-07-30
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.28917
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr28917-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>Although fatigue, sleep disturbance, depression, and anxiety are associated with pain in breast cancer patients, it is unknown whether acupuncture can decrease these comorbid symptoms in cancer patients with pain. The objective of this study was to evaluate the effect of electroacupuncture (EA) on fatigue, sleep, and psychological distress in breast cancer survivors who experience joint pain related to aromatase inhibitors (AIs).</p> </sec> <sec id="cncr28917-sec-0002" sec-type="section"> <title>METHODS</title> <p>The authors performed a randomized controlled trial of an 8‐week course of EA compared with a waitlist control (WLC) group and a sham acupuncture (SA) group in postmenopausal women with breast cancer who self‐reported joint pain attributable to AIs. Fatigue, sleep disturbance, anxiety, and depression were measured using the Brief Fatigue Inventory (BFI), the Pittsburgh Sleep Quality Index (PSQI), and the Hospital Anxiety and Depression Scale (HADS). The effects of EA and SA versus WLC on these outcomes were evaluated using mixed‐effects models.</p> </sec> <sec id="cncr28917-sec-0003" sec-type="section"> <title>RESULTS</title> <p>Of the 67 randomly assigned patients, baseline pain interference was associated with fatigue (Pearson correlation coefficient [<italic>r</italic>]=0.75; <italic>P</italic> < .001), sleep disturbance (<italic>r</italic>=0.38; <italic>P</italic>=.0026), and depression (<italic>r</italic>=0.58; <italic>P</italic> < .001). Compared with the WLC condition, EA produced significant improvements in fatigue (<italic>P</italic>=.0095), anxiety (<italic>P</italic>=.044), and depression (<italic>P</italic>=.015) and a nonsignificant improvement in sleep disturbance (<italic>P</italic>=.058) during the 12‐week intervention and follow‐up period. In contrast, SA did not produce significant reductions in fatigue or anxiety symptoms but did produce a significant improvement in depression compared with the WLC condition (<italic>P</italic>=.0088).</p> </sec> <sec id="cncr28917-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>Compared with usual care, EA produced significant improvements in fatigue, anxiety, and depression; whereas SA improved only depression in women experiencing AI‐related arthralgia. <bold><italic>Cancer</italic> 2014;120:3744–3751.</bold> © <italic>2014 American Cancer Society</italic>.</p> </sec> </abstract>